Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480, a novel CELMoD agent, in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM).

被引：0

作者：

Wong, Lilly

Jimenez Nunez, Maria Dolores

Bahlis, Nizar J.

Vangsted, Annette J.

Ramasamy, Karthik

Trudel, Suzanne

Martinez, Joaquin

Mateos, Maria-Victoria

Rodriguez Otero, Paula

Lonial, Sagar

Popat, Rakesh

Oriol, Albert

Karanes, Chatchada

Orlowski, Robert Z.

Berdeja, Jesus G.

Wang, Maria

Lamba, Manisha

Pourdehnad, Michael

Pierce, Daniel W.

Richardson, Paul G.

机构：

[1] Bristol Myers Squibb, San Diego, CA USA

[2] Celgene Res SLU, Seville, CA, Spain

[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[4] Rigshosp, Dept Haematol, Copenhagen, Denmark

[5] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Oxford, England

[6] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[7] Univ Complutense Madrid, Hosp Octubre 12, Dept Hematol, H120 CNIO Clin Res Unit,CIBERONC, Madrid, Spain

[8] Univ Hosp Salamanca IBSAL, Salamanca, Spain

[9] Univ Clin Navarra, Ctr Appl Med Res CIMA, IDISNA, Pamplona, Spain

[10] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[11] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England

[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain

[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain

[14] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA

[15] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[16] Sarah Cannon Ctr Blood Canc, Nashville, TN USA

[17] Bristol Myers Squibb, Summit, NJ USA

[18] Bristol Myers Squibb, San Francisco, CA USA

[19] Dana Farber Canc Inst, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8531

引用

页数：2

共 50 条

[21] Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific 1-cell engager, in relapsed andfor refractory multiple myeloma (RRMM).
Topp, Max S.
Attal, Michel
Langer, Christian
Moreau, Philippe
Facon, Thierry
Dull, Johannes
Hebraudt, Benjamin
Gomez-Roca, Carlos
Munzert, Gerd Michael
Gracien, Edith
Zugmaier, Gerhard
Einsele, Hermann
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[22] Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
Isamu Sugiura
Satomi Terabe
Tomohiro Kinoshita
Kazuhito Yamamoto
Masashi Sawa
Yukiyasu Ozawa
Yoshiko Atsuta
Ritsuro Suzuki
Kazuyuki Shimizu
International Journal of Hematology, 2015, 102 : 434 - 440
[23] A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma
Shinsuke Iida
Kazutaka Sunami
Hironobu Minami
Kiyohiko Hatake
Risa Sekiguchi
Kazuto Natsume
Norifumi Ishikawa
Mikael Rinne
Masafumi Taniwaki
International Journal of Hematology, 2021, 113 : 797 - 806
[24] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Hongmei Jing
Li Yang
Junyuan Qi
Lugui Qiu
Chengcheng Fu
Junmin Li
Min Yang
Ming Qi
Ni Fan
Jia Ji
Jiajia Lu
Yunan Li
Jie Jin
Annals of Hematology, 2022, 101 : 2679 - 2690
[25] An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma
Kropff, Martin
Kienast, Joachim
Bisping, Guido
Berdel, Wolfgang E.
Gaschler-Markefski, Birgit
Stopfer, Peter
Stefanic, Martin
Munzert, Gerd
ANTICANCER RESEARCH, 2009, 29 (10) : 4233 - 4238
[26] Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)
Jing, Hongmei
Yang, Li
Qi, Junyuan
Qiu, Lugui
Fu, Chengcheng
Li, Junmin
Yang, Min
Qi, Ming
Fan, Ni
Ji, Jia
Lu, Jiajia
Li, Yunan
Jin, Jie
ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2679 - 2690
[27] Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Yee, Andrew J.
Laubach, Jacob P.
Nooka, Ajay K.
O'Donnell, Elizabeth K.
Weller, Edie A.
Couture, Nicole R.
Wallace, Ellen E.
Burke, Jill N.
Harrington, Cynthia C.
Puccio-Pick, Marie
Laadem, Abderrahmane
Sherman, Matthew L.
Raje, Noopur S.
BLOOD, 2015, 126 (23)
[28] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
Ghobrial, Irene M.
Weller, Edie
Vij, Ravi
Munshi, Nikhil C.
Banwait, Ranjit
Bagshaw, Meghan
Schlossman, Robert
Leduc, Renee
Chuma, Stacey
Kunsman, Janet
Laubach, Jacob
Jakubowiak, Andrzej J.
Maiso, Patricia
Roccaro, Aldo
Armand, Philippe
Dollard, Akari
Warren, Diane
Harris, Brianna
Poon, Tiffany
Sam, Amy
Rodig, Scott
Anderson, Kenneth C.
Richardson, Paul G.
LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
[29] A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib In Combination With Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma
Berenson, James R.
Klein, Leonard
Rifkin, Robert M.
Patel, Priti
Dixon, Sandra
Ou, Ying
Cartmell, Alan
BLOOD, 2013, 122 (21)
[30] Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Ailawadhi, Sikander
Stiff, Patrick J.
Maharaj, Michele
Oliver, Katherine
Callander, Natalie Scott
BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →